Diabetes Metab J.  2016 Oct;40(5):418-419. 10.4093/dmj.2016.40.5.418.

Letter: Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:297-307)

• Yi D

• KMID: 2354616
• DOI: http://doi.org/10.4093/dmj.2016.40.5.418

Abstract

No abstract available.

MeSH Terms

Diabetes Mellitus, Type 2*
Gastroesophageal Reflux*
Humans
Prevalence*
Risk Factors*

Reference

1. Lluch I, Ascaso JF, Mora F, Minguez M, Pena A, Hernandez A, Benages A. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol. 1999; 94:919–924.

2. Wang X, Pitchumoni CS, Chandrarana K, Shah N. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol. 2008; 14:709–712.

3. Sun XM, Tan JC, Zhu Y, Lin L. Association between diabetes mellitus and gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2015; 21:3085–3092.

4. Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am. 2013; 42:809–832.

5. Ha JO, Lee TH, Lee CW, Park JY, Choi SH, Park HS, Lee JS, Lee SH, Seo EH, Kim YH, Kang YW. Prevalence and risk factors of gastroesophageal reflux disease in patients with type 2 diabetes mellitus. Diabetes Metab J. 2016; 40:297–307.

6. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900–1920.

7. Punjabi P, Hira A, Prasad S, Wang X, Chokhavatia S. Review of gastroesophageal reflux disease (GERD) in the diabetic patient. J Diabetes. 2015; 7:599–609.

8. Hershcovici T, Jha LK, Gadam R, Cui H, Gerson L, Thomson S, Fass R. The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease. J Clin Gastroenterol. 2012; 46:662–668.

9. Crouch MA, Mefford IN, Wade EU. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med. 2012; 25:50–54.

10. Singh PK, Hota D, Dutta P, Sachdeva N, Chakrabarti A, Srinivasan A, Singh I, Bhansali A. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2012; 97:E2105–E2108.